{
    "clinical_study": {
        "@rank": "16457", 
        "arm_group": {
            "arm_group_label": "single arm study/ non randomized trial", 
            "arm_group_type": "Other", 
            "description": "FOLFORINOX"
        }, 
        "brief_summary": {
            "textblock": "The FOLFIRINOX protocol seems a promising protocol as attack treatment of a rectum cancer,\n      with an objective response rate of about 70 %. This phase II is to investigate if this\n      systematic attack chemotherapy could control at the same time the rectal tumor and the\n      synchronous metastasis without compromising secondarily the tumor or the metastasis\n      resection or a radiochemotherapy administration.\n\n        1. The main objective of the trial is to investigate the tumoral control rate at 4 months,\n           according to the RECIST criteria (version 1.1).\n\n        2. The secondary objectives are:\n\n             -  safety of the treament,\n\n             -  rate of local failure and local complication (occlusion, important bleedings,\n                resistant pains with morphinic treatment, perforation),\n\n             -  survival without local failure (radiological or clinical progression of the rectal\n                cancer or local complication),\n\n             -  rectal tumor response rate (CT scan, MRI and endocopy),\n\n             -  metastasis response rate,\n\n             -  disease free survival after complete resection (of primitive tumor and\n                metastases),\n\n             -  progression free survival (local or distal),\n\n             -  overall survival, quality of life (QLQ-C30 + CR 29)."
        }, 
        "brief_title": "First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Adenocarcinoma of Rectum", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Rectal Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The FOLFIRINOX protocol seems a promising protocol as attack treatment of a rectum cancer,\n      with an objective response rate of about 70 %. This phase II is to investigate if this\n      systematic attack chemotherapy could control at the same time the rectal tumor and the\n      synchronous metastasis without compromising secondarily the tumor or the metastasis\n      resection or a radiochemotherapy administration.\n\n        1. The main objective of the trial is to investigate the tumoral control rate at 4 months,\n           according to the RECIST criteria (version 1.1).\n\n        2. The secondary objectives are:\n\n             -  safety of the treament,\n\n             -  rate of local failure and local complication (occlusion, important bleedings,\n                resistant pains with morphinic treatment, perforation),\n\n             -  survival without local failure (radiological or clinical progression of the rectal\n                cancer or local complication),\n\n             -  rectal tumor response rate (CT scan, MRI and endocopy),\n\n             -  metastasis response rate,\n\n             -  disease free survival after complete resection (of primitive tumor and\n                metastases),\n\n             -  progression free survival (local or distal),\n\n             -  overall survival, quality of life (QLQ-C30 + CR 29).\n\n        3. Inclusion and non inclusion criteria\n\n        4. Treatment\n\n        5. Follow up"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven adenocarcinoma of the rectum, the lower pole less than 15 cm\n             from the anal verge\n\n          -  Patient should not have receive any treatment for cancer\n\n          -  Synchronous metastases with unresectable hepatic and/or lung localization  or\n             uncertain resectability (potentially resectable)\n\n          -  Measurable lesions by RECIST 1.1 (metastasis and primary cancer of the rectum)\n\n          -  Age \u2265 18 years\n\n          -  WHO \u2264 2\n\n          -  ANC \u2265 1.5 x 10 9/L, platelets \u2265 100 x 10 9/L, creatinine clearance \u2265 60 mL/min\n\n          -  Hemoglobin \u2265 10 g /dL\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  Rectal Cancer in occlusion requiring surgery or a prosthesis in emergency\n\n          -  Rectal bleeding severe and active\n\n          -  Prior pelvic irradiation\n\n          -  History of cancer, except non-melanoma skin cancer, carcinoma in situ of the cervix\n             treated curatively and other cancers treated curatively if they do not relapse over 3\n             years,\n\n          -  Hepatic impairment (total bilirubin> 1.5 x upper limit of normal (ULN) and serum\n             albumin <25g / L); known Gilbert's disease\n\n          -  Uncontrolled severe infection,\n\n          -  Severe pain (VAS> 5/10) uncontrollable by opioid therapy\n\n          -  Symptomatic sensorimotor peripheral neuropathy\n\n          -  Pregnant or lactating patients or patient of both sexes with childbearing potential\n             and not using adequate contraception method\n\n          -  Patient receiving or having received an experimental therapy within 4 weeks prior to\n             enter into the study or participating in another clinical study of other experimental\n             drugs\n\n          -  Known hypersensitivity to any component of the treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01674309", 
            "org_study_id": "FFCD 1102"
        }, 
        "intervention": {
            "arm_group_label": "single arm study/ non randomized trial", 
            "description": "INTRAVENOUS administration", 
            "intervention_name": "FOLFORINOX", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Colmar", 
                    "country": "France", 
                    "zip": "68024"
                }, 
                "name": "Colmar Ch"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis", 
        "overall_official": {
            "affiliation": "CHU de La Piti\u00e9 Salpetri\u00e8re - APHP", 
            "last_name": "Jean-Baptiste BACHET, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": [
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The tumor control rate of the primary site and metastasis is defined as Complete response or Partial response or stability according to RECIST 1.1 criteria", 
            "measure": "Tumor control rate of the primary tumor and metastasis", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01674309"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of patients presenting the main toxicities during the study", 
                "measure": "Toxicity of the treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 4 months after Last Patient First Visit"
            }, 
            {
                "description": "The rate is defined as the clinical progression or a radiological progression of the rectum cancer or a local complication due to the treatment or due to the progression", 
                "measure": "rate of local failure and local complication (occlusion, important bleedings, resistant pains with morphinic treatment, perforation)", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "The survival time is defined as the time between the patient's inclusion and the time of the local failure or patient's death", 
                "measure": "survival without local failure (radiological or clinical progression of the rectal cancer or local complication)", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 months after Last Patient First Visit"
            }, 
            {
                "description": "The rectal tumor response rate is the Complete response or the Partial response of the rectal tumor using RECIST 1.1 criteria", 
                "measure": "rectal tumor response rate (CT scan, MRI and endocopy)", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "The metastasis tumor response rate is the Complete response or the Partial response of metastasis using RECIST 1.1 criteria", 
                "measure": "metastasis response rate", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }
        ], 
        "source": "Federation Francophone de Cancerologie Digestive", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Federation Francophone de Cancerologie Digestive", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012", 
        "why_stopped": "suspended for the step 1 analysis"
    }
}